Literature DB >> 28590316

RECURRENCE OF CHOROIDAL NEOVASCULARIZATION LESION ACTIVITY AFTER AFLIBERCEPT TREATMENT FOR AGE-RELATED MACULAR DEGENERATION.

Tomotaka Wakazono1, Kenji Yamashiro, Akio Oishi, Sotaro Ooto, Hiroshi Tamura, Yumiko Akagi-Kurashige, Masayuki Hata, Ayako Takahashi, Akitaka Tsujikawa, Nagahisa Yoshimura.   

Abstract

PURPOSE: To examine the recurrence rate of choroidal neovascularization (CNV) lesion activity in age-related macular degeneration (AMD) and associated factors after 1-year aflibercept treatment.
METHODS: Age-related macular degeneration eyes with 1-year aflibercept fixed-regimen treatment and a follow-up period of at least 18 months from the initial aflibercept injection for treatment-naive exudative AMD were retrospectively evaluated. The recurrence rate was examined. Age, gender, visual acuity, AMD subtype, greatest linear dimension, and retinal and choroidal thicknesses at the 12th month examination were compared between eyes with and without recurrence. Presence of remnant polyps and pigment epithelial detachment (PED) morphology were also compared in polypoidal choroidal vasculopathy (PCV) eyes.
RESULTS: Of the 98 eyes studied, 69 displayed a dry macula at the 12th month examination; 43.7% exhibited recurrence during the subsequent 12-month period in Kaplan-Meier analysis. Although no factors associated with recurrence were detected in AMD, remnant polyps and pigment epithelial detachment morphology at the 12th month examination were significantly associated with recurrence in polypoidal choroidal vasculopathy (P = 0.018 and 0.048, respectively).
CONCLUSION: Continuous, proactive treatment would be considered overtreatment for more than half of the AMD eyes that achieved a dry macula. Angiography and optical coherence tomography analyses may be useful for predicting recurrence in polypoidal choroidal vasculopathy eyes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28590316     DOI: 10.1097/IAE.0000000000001451

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

1.  Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-PI3K/AKT signaling pathway.

Authors:  Lijuan Sun; Tonglie Huang; Wenqin Xu; Jiaxing Sun; Yang Lv; Yusheng Wang
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

2.  Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy.

Authors:  Keiichi Nishikawa; Akio Oishi; Masayuki Hata; Masahiro Miyake; Sotaro Ooto; Kenji Yamashiro; Manabu Miyata; Hiroshi Tamura; Naoko Ueda-Arakawa; Ayako Takahashi; Yu Kawashima; Akitaka Tsujikawa
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

3.  Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy.

Authors:  Seonghee Choi; Hae Min Kang; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-27       Impact factor: 3.117

4.  Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy.

Authors:  Norihiro Nagai; Misa Suzuki; Sakiko Minami; Toshihide Kurihara; Mamoru Kamoshita; Hideki Sonobe; Kazuhiro Watanabe; Atsuro Uchida; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

5.  Imaging Biomarkers of 1-Year Activity in Type 1 Macular Neovascularization.

Authors:  Eliana Costanzo; Mariacristina Parravano; Daniela Giannini; Enrico Borrelli; Riccardo Sacconi; Giuseppe Querques
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

6.  Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration.

Authors:  Junyeop Lee; You Na Kim; June-Gone Kim
Journal:  J Clin Med       Date:  2022-03-11       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.